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ABSTRACT  28 
Intake of fish and omega-3 (n-3) fatty acids is associated with reduced concentration of 29 
plasma triacylglycerols (TAG) but the mechanisms are not fully clarified. Stearoyl-CoA 30 
desaturase-1 (SCD1) activity, governing TAG synthesis, is affected by n-3 fatty acids. 31 
Peripheral blood mononuclear cells (PBMC) display expression of genes involved in lipid 32 
metabolism. The aim of the present study was to estimate whether intake of lean and fatty fish 33 
would influence n-3 fatty acids composition in plasma phospholipids (PL), serum TAG, 34 
18:1n-9/18:0 ratio in plasma PL, as well as PBMC gene expression of SCD1 and fatty acid 35 
synthase (FAS). Healthy males and females (n = 30), aged 20—40, consumed daily for 15 36 
days either 150 g of cod, salmon, or potato (control). During intervention docosahexaenoic 37 
acid (DHA, 22:6n-3) increased in the cod group (P < 0.05), while TAG concentration 38 
decreased (P < 0.05). In the salmon group both eicosapentaenoic acid (EPA, 20:5n-3) and 39 
DHA increased (P < 0.05) whereas TAG concentration and the 18:1n-9/18:0 ratio decreased 40 
(P < 0.05). Reduction of the 18:1n-9/18:0 ratio was associated with a corresponding lowering 41 
of TAG (P < 0.05) and an increase in EPA and DHA (P < 0.05). The mRNA levels of SCD1 42 
and FAS in PBMC were not significantly altered after intake of cod or salmon when 43 
compared with the control group. In conclusion, both lean and fatty fish may lower TAG, 44 
possibly by reducing the 18:1n-9/18:0 ratio related to allosteric inhibition of SCD1 activity, 45 
rather than by influencing the synthesis of enzyme protein. 46 
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Abbreviations 50 
CE  Cholesterol esters 51 
CVD  Cardiovascular disease 52 
DHA  Docosahexaenoic acid 53 
EPA  Eicosapentaenoic acid 54 
FAS  Fatty acid synthase 55 
GUSβ  Glucuronidase-beta 56 
HDL-C High density lipoprotein cholesterol 57 
LA  Linoleic acid 58 
LDL-C Low density lipoprotein cholesterol 59 
n-3  Omega-3 60 
PBMC  Peripheral blood mononuclear cells 61 
PL  Phospholipids 62 
PPARα Peroxisome-proliferator activated receptor alpha 63 
PUFA  Polyunsaturated fatty acids 64 
SCD1  Stearoyl-CoA desaturase-1 65 
SREBP1 Sterol regulatory element-binding protein 1 66 
TBP  TATA binding protein 67 
TAG  Triacylglycerols 68 
VLDL  Very low density lipoprotein69 
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INTRODUCTION 70 
Numerous epidemiological studies have demonstrated reduced risk of cardiovascular diseases 71 
(CVD) in response to increased intake of fish or fish oils [1-3]. Especially fatty fish is a major 72 
source of long chain omega-3 polyunsaturated fatty acids (n-3 PUFA), such as 73 
eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). Many of 74 
the beneficial health effects of fish and fish oils have been linked to intake of these fatty acids 75 
[4-10]. Serum triacylglycerols (TAG) is recognized as an independent risk factor of CVD [11] 76 
and marine n-3 fatty acids in high doses (>3g/day) have been shown to reduce serum TAG by 77 
25—30 % [12-15]. The magnitude of the TAG reducing effect seems to be dependent on n-3 78 
fatty acid dose and baseline TAG concentrations [14, 16]. The American heart association 79 
(AHA) recommend the consumption of a variety of fish (preferably fatty fish) at least twice a 80 
week as guidance for healthy people [17]. However, intake of lean fish is also known to 81 
provide health benefits [18-20] in which one effect is reduced serum TAG [20]. Whether the 82 
health beneficial effects of lean fish are related to the n-3 fatty acids content, or to other 83 
bioactive components, is not known. 84 
The molecular mechanisms involved in the hypotriglyceridemic effect of marine n-3 fatty 85 
acids are not clarified. In general, the effects could be due to reduced production, and/or to 86 
increased elimination of TAG [2]. In the present work we have focused upon some aspects of 87 
the synthesis of TAG. In the fasted state serum TAG is mainly carried in very low density 88 
lipoproteins (VLDL), which are synthesized and secreted in the liver. TAG, cholesterol esters 89 
(CE) and phospholipids (PL) in VLDL preferably contain monounsaturated fatty acids, i.e. 90 
palmitoleic (16:1n-7) and oleic (18:1n-9) acid. The rate limiting enzyme for the synthesis of 91 
these fatty acids is stearoyl-CoA desaturase-1 (SCD1 or Δ9 desaturase). Mice lacking SCD1 92 
have reduced hepatic lipogenesis and lower plasma TAG concentration [21, 22]. Accordingly, 93 
one mechanism by which fish intake decreases serum TAG could be inhibition of desaturase 94 
  
6 
activities in the liver, caused directly or indirectly by some of the constituents in fish. In 95 
general, the rate of an enzyme catalyzed reaction may be influenced by the amount of enzyme 96 
protein, by phosphorylation and dephosphorylation of the enzyme, or by allosteric regulation 97 
[23]. Oleic acid is a major constituent of TAG produced by de novo lipogenesis, and therefore 98 
the 18:1n-9/18:0 ratio, i.e. a product/precursor ratio, in plasma may be used to estimate SCD1 99 
activity [22, 24-26]. Animal studies have demonstrated that marine n-3 fatty acids can 100 
suppress hepatic lipogenesis [4], and one regulatory mechanism may be inhibition of  SCD1 101 
activity [27] or by transcriptional regulation of sterol regulatory element-binding protein 1 102 
(SREBP1) [28]. SREBP1 is regulating the expression of lipogenic genes such as SCD1 and 103 
fatty acid synthase (FAS) [28], and an inhibition of SREBP1 by n-3 fatty acids will cause a 104 
down-regulation of these genes [29]. To study whether n-3 fatty acids might influence human 105 
hepatic gene expression in vivo is challenging. However, since human PBMC can display the 106 
expression of genes involved in lipid metabolism [30-35] we have chosen PBMC as a test 107 
system.  108 
The aim of the present exploratory study was accordingly to investigate whether daily intake 109 
of lean and fatty fish for two weeks would influence n-3 fatty acids composition in plasma 110 
PL, serum TAG levels, 18:1n-9/18:0 ratio in plasma PL (an estimated indication of SCD1 111 
activity), and to assess SCD1 and FAS by their mRNA levels in PBMC, in healthy subjects.112 
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SUBJECTS AND METHODS 113 
This study is an extension of a previous study involving 38 healthy subjects randomized to 114 
four different intervention groups consuming either salmon (n = 11), cod (n = 9), blue mussel 115 
(n = 8) or potato (control) (n = 10) in order to study arsenic metabolism (Molin et al., 116 
manuscript in preparation). The opportunity was taken to investigate lean versus fatty fish in 117 
this exploratory study (n = 30). 118 
Subjects Thirty subjects (7 men and 23 women) aged 20—40 were recruited from Akershus 119 
University College, Lillestrøm, Norway. Healthy subjects with C-reactive protein (CRP) <10 120 
mg/L using no medication, except for oral contraceptives (female subjects (n = 11), all 121 
subjects maintained the use throughout the study, except for one subject in the control group), 122 
were included in this study. Smoking, pregnancy and lactation were exclusion criteria. 123 
Additionally, subjects who had a habitual seafood consumption of more than three servings 124 
per week were excluded. All subjects were compliant with the protocol throughout the study. 125 
Compliance was assessed based on observations of the participants during the test meals, 126 
served at the University College and the amount of leftovers after the experimental period. 127 
Compliance was estimated to be 95—100 % in all three groups. The study protocol was 128 
approved by Regional Committee of Medical Ethics in Norway. Written informed consent for 129 
participation was obtained from each subject and it complied with the Declaration of Helsinki.  130 
Study design A fifteen days randomized controlled parallel-group study was conducted. The 131 
participants were randomized but not stratified by gender, and therefore by chance all the 132 
subjects in the salmon group were females. The subjects received a daily test meal of 150 g of 133 
either farmed salmon (Salmo salar) (n = 11), cod (Gadus morhua) (n = 9) or potato (control) 134 
(n = 10) for 15 consecutive days. The subjects were carefully instructed not to eat any seafood 135 
except the seafood provided in the study, and not to take any dietary supplements during the 136 
intervention period. Marine n-3 supplements (including cod liver oil) were prohibited 5 weeks 137 
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prior to and during the study. Each subject was requested not to change dietary and exercise 138 
habits during the study. 139 
Test meals A homogenous mixture of cod or salmon fillets was prepared as fish puddings and 140 
cut into cubes. Potatoes were cooked and cut into cubes. The test meal menu was a 7-day 141 
menu which was served hot and repeated twice and all the dishes were similar for all 142 
intervention groups except for the fish/potato. The test meal was served at Akershus 143 
University College Monday—Friday, and lunch boxes to bring home were provided for the 144 
weekend. 145 
Blood sampling and biochemical analysis Blood samples were collected from fasting 146 
subjects (minimum12 h) at the same time (between 8 a.m. and 10 a.m.) at baseline and at end 147 
of study. PBMC were isolated using cell preparation tubes (CPT) according to the 148 
manufacturer’s instructions (Becton, Dickinson and Company, NJ 07417, USA). 149 
Determination of serum total cholesterol (total-C), HDL cholesterol (HDL-C), LDL 150 
cholesterol (LDL-C), TAG and CRP was performed using routine laboratory methods (Fürst 151 
Medical laboratory, Norway). Plasma was obtained from EDTA tubes and kept frozen (-70 152 
ºC) until analysis. 153 
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Fatty acid composition in fish Homogenous mixture of cod or salmon fillets were kept 154 
frozen (-20 ºC) until analysis and total lipids were extracted by adding chloroform/methanol 155 
(2:1, vol/vol), and nonadecylic acid (19:0) was added as internal standard. The samples were 156 
filtered, saponified, and methylated using 12% BF3 in methanol. Fatty acid composition of 157 
total lipids was analyzed using methods as described earlier [36, 37]. 158 
Fatty acid composition in plasma PL was determined as previously reported [38]. The 159 
18:1n-9/18:0 ratio was calculated from the fatty acid composition in plasma PL and used as an 160 
estimate of desaturase activity.  161 
RNA isolation and Quantitative Real-time Polymerase Chain Reaction (Q-RT-PCR) 162 
Total RNA was extracted from PBMC using a combination of TRIzol Reagent (Invitrogen, 163 
Carlsbad, CA, USA) and RNeasy mini kit (Qiagen, Hilden, Germany) purified with RNAse-164 
free DNAse (Invitrogen). Subsequently the samples were stored in RNAse-free water at -165 
80°C. RNA quality was measured on an Agilent Bioanalyser 2100 system (Agilent 166 
Technologies, Santa Clara, CA, USA) and showed RNA Integrity Numbers (RIN) between 167 
8.7 and 9.8. Total RNA yield was measured on a Nanodrop ND-1000 Spectrophotometer 168 
(NanoDrop Technologies, Wilmington, Delaware, USA). For cDNA synthesis, 500 ng RNA 169 
of each total RNA sample was reverse-transcribed by Super Script (Invitrogen) according to 170 
the manufacturer’s protocol, using oligo dT as primers. The Taqman real-time polymerase 171 
chain reaction (RT-PCR) technique was used to quantify the mRNA expression of each gene. 172 
cDNA corresponding to fifteen ng RNA was applied to each well and each sample was run in 173 
triplets. Quantification was performed using the relative standard curve method. A 174 
combination of aliquots from all cDNA samples was made and diluted in order to make a 175 
dilution curve that was included on each plate. The points on the standard curve corresponded 176 
to 50, 25, 12.5 and 6.25 ng RNA. The average of the three values measured per gene per 177 
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sample were divided by the average of the corresponding combined Glucuronidase-beta 178 
(GUS) and TATA binding protein (TBP) values, generating a normalized value used to 179 
compare the relative amount for each gene in the different samples. GUS and TBP were 180 
chosen as endogenous genes due to the results from running a TaqMan Human Endogenous 181 
Control Plate-test from Applied Biosystems (data not shown). The primers and probes for 182 
GUS and TBP were initially designed as three assays per gene, and validated for efficiency 183 
and specificity. The best of the three was then chosen. The primers and probe for the 184 
GUSassay were: forward primer: 5’-GAAAATATGTGGTTGGAGAGCTCATT-3’, probe: 185 
5’-CCAGCACTCTCGTCGGTGACTGTTCA-3’ and reverse primer: 5’-186 
CCGAGTGAAGATCCCCTTTTTA-3’. TBP forward primer: 5’- 187 
CTGGAAAAGTTGTATTAACAGGTGC-3’, probe: 5’-188 
AGCAGAAATTTATGAAGCATTTGAAAACATCTACCCTATT-3’ and reverse primer: 5’-189 
CATTACGTCGTCTTCCTGAATC-3’. All other genes were measured by “single tube” 190 
assays, which are a premade combination of primers and probe, specific for the gene to be 191 
determined (Applied Biosystems, Foster City, CA) and utilized according to the 192 
manufacturer’s protocol. SCD1 (Δ-9 desaturase): no. Hs01682761_m1 and FAS: no. 193 
Hs00188012_m1. RT-PCR was carried out on a 7900HT real time PCR machine from 194 
Applied Biosystems (Applied Biosystems, Foster City, CA, USA).  195 
Statistical analysis Probability values (asymptotic) were considered statistically significant at 196 
a value of P ≤ 0.05. Nonparametric tests were used due to the small sample size and values 197 
are given as median (25—75 percentile). Percent change is calculated from median values.  198 
Differences between the randomisation groups were analysed at end of study (baseline 199 
adjusted values). Delta values refer to values at end of study minus baseline values for the 200 
plasma parameters, while gene expression delta values refer to values at end of study divided 201 
with baseline values (fold change). The present study is considered an exploratory study and 202 
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therefore no adjustment for multiple testing was performed. Mann-Whitney U test and 203 
Wilcoxon matched-pair signed-rank test were used to either compare changes between groups 204 
or within-groups, respectively. Coefficients of correlation were calculated
 by the Spearman’s 205 
rho test. The SPSS for Windows (version 18.0) was used for all statistical analyses.206 
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RESULTS  207 
Baseline characteristics There were no significant differences in baseline characteristics 208 
between the study groups (Table 1).  209 
Intake of n-3 fatty acids from the intervention meals Daily intake of EPA and DHA 210 
provided from the seafood lunch meal were 1.4 and 1.7 g/day in the salmon group while the 211 
total daily n-3 fatty acids intake was 5.4 g (Table 2). Corresponding intake were 0.048 and 212 
0.086 g/day in the cod group with a total n-3 intake of 0.15 g/day. The potatoes did not 213 
contain any marine n-3 fatty acids, but total intake of n-3 fatty acids (α-linolenic acid, 18:3n-214 
3) was 0.14 g/day (Table 2). 215 
Fatty acid profile in plasma PL Daily intake of 150 g fish for 15 days significantly 216 
increased the amount of total n-3 fatty acids (EPA and DHA) in plasma PL in both the cod (P 217 
= 0.008) and the salmon (P < 0.001) groups, compared to the control group (Table 3). DHA 218 
increased in the cod group (P = 0.003) while both EPA and DHA increased in the salmon 219 
group (P < 0.001 and P = 0.001, respectively), compared to the control group. The baseline 220 
values of EPA and DHA were not different between the groups, nor were any of the other 221 
fatty acids in the plasma PL. 222 
Serum concentration of TAG, total-C, HDL-C and LDL-C As shown in Table 4, the 223 
serum concentration of TAG was significantly decreased both in the cod group (P = 0.02) and 224 
in the salmon group (P = 0.003) as compared with the control group. The reduction was 225 
significant within the cod (P = 0.05) and the salmon (P = 0.008) groups, corresponding to a 226 
reduction of 11 % and 22 %, respectively. No significant alteration in the TAG concentration 227 
was seen within the control group. Serum HDL-C was significantly increased after intake of 228 
salmon compared with the control group (P = 0.009), and the within-group increase was 5 % 229 
(P = 0.02). Serum total-C and serum LDL-C was not changed between or within any of the 230 
groups (Table 4). 231 
  
13 
The change in both EPA and DHA in plasma PL correlated negatively with the change in 232 
TAG (n = 30) (r = -0.5, P = 0.007 and r = -0.4, P = 0.04, respectively) (Data not shown). 233 
Effects on 18:1n-9/18:0 ratio in plasma PL As shown in Figure 1, there was a significant 234 
reduction in the 18:1n-9/18:0 ratio in plasma PL in the salmon group compared with the 235 
control group (P = 0.004), and a significant within-group reduction after intake of cod (P = 236 
0.04) and salmon (P = 0.003) for two weeks. In contrast, there was no significant within-237 
group change in the control group during the experiment (Figure 1).  238 
Relationship between serum TAG, marine n-3 fatty acids and 18:1n-9/18:0 ratio in 239 
plasma PL As illustrated in Figure 2, there was a positive correlation (r = 0.5, P = 0.01) 240 
between change in the 18:1n-9/18:0 ratio and change in serum TAG (n = 30) (Figure 2).  241 
Since previous studies suggest that SCD1 might be regulated by EPA and DHA, we 242 
investigated whether the 18:1n-9/18:0 ratio was related to n-3 fatty acids in plasma PL. 243 
Indeed, as shown in Figure 3, there was a highly significant negative correlation between the 244 
increase in marine n-3 fatty acids in plasma PL and reduction in the 18:1n-9/18:0 ratio (n = 245 
30) (r = -0.7, P < 0.001). 246 
Effects on mRNA expression in PBMC There was no significant change in mRNA level of 247 
the two selected lipogenesis related genes in the two intervention groups when compared to 248 
the control group (Figure 4). However, mRNA level of FAS was significantly increased 249 
within the salmon group (P = 0.008) (Figure 4).250 
  
14 
DISCUSSION 251 
In this exploratory study in healthy subjects we found that a short term intake of both lean and 252 
fatty fish decreased serum TAG levels (Table 4) and 18:1n-9/18:0 ratio in plasma PL (an 253 
estimated indication of SCD1 activity) (Figure 1). The marine n-3 fatty acid DHA in plasma 254 
PL increased significantly after intake of lean and fatty fish, while EPA increased only after 255 
fatty fish intake (Table 3).  256 
Most studies have investigated health effects after intake of relatively high doses of n-3 fatty 257 
acids, often administered as supplements. In the present study n-3 fatty acids were provided as 258 
regular fish meals. The hypotriglyceridemic effect of fatty fish has been largely attributed to 259 
n-3 fatty acids, and our finding of a decrease in serum TAG in the salmon group is consistent 260 
with previous reports [12]. However, as shown in the present study also cod significantly 261 
reduced serum TAG. The main carriers of TAG in fasting plasma are VLDL, and in general 262 
the hypotriglyceridemic effect of fish could be related to reduced production, and/or to 263 
increased elimination of these lipoproteins. The present work focused only upon some aspects 264 
of TAG synthesis. TAG, CE and PL in VLDL preferably contain monounsaturated fatty acids, 265 
i.e. palmitoleic and oleic acid. Since SCD1 is the rate limiting enzyme for the synthesis of 266 
these fatty acids, one mechanism by which fish intake decreases serum TAG could be a 267 
reduced hepatic desaturase activity, caused directly or indirectly by some of the constituents 268 
in fish. Fish intake might influence the amount of SCD1 enzyme protein and during the past 269 
decade, several human intervention studies have focused on diet-induced gene interactions 270 
using PBMC as a model system [33, 34, 39, 40]. From the present work it would appear that 271 
fish intake might not affect the amount of enzyme protein in PBMC, since there was no 272 
alteration in mRNA levels of SCD1 in response to fish intake. Even so, this observation does 273 
not rule out the possibility that fish/n-3 fatty acids intake affect the hepatic SCD1 mRNA 274 
levels, which have been reported by others [25, 41-45]. Human PBMC display the expression 275 
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of genes involved in lipid metabolism [30-35, 46, 47] and recently we showed that n-3 fatty 276 
acids regulate lipid gene expression in ex vivo PBMC [48]. Human research has limitations in 277 
tissue availability except for blood samples which is readily and easily obtained. It has been 278 
shown that the expression of genes involved in lipid metabolism are regulated in PBMC in a 279 
similar pattern as in liver upon fasting [33] and several dietary intervention studies have 280 
shown that expression of genes involved in lipid metabolism is altered in PBMC after 281 
intervention [34, 35, 46, 47]. This indicates that PBMC is a potentially good model system in 282 
dietary intervention studies to study genes related to lipid metabolism. However, liver cells 283 
and PBMC do have different biochemical properties and the use of PBMC as a model system 284 
of hepatic activity is at its very beginning and weaknesses with this model system may exist. 285 
It is also likely that due to the small sample size in the present study, type 2 errors are liable to 286 
occur and a false effect on gene expression cannot be ruled out. The increase in FAS mRNA 287 
in PBMC after intake of salmon in the present work (Figure 4) is in contrast to previous 288 
observations from in vitro and mice studies where it has been shown that PUFA suppress the 289 
hepatic expression of FAS [25, 28, 29, 49-51]. Even though the present mRNA level of FAS 290 
in the salmon group has two outliers, the within-group change is still significant (P = 0.02) 291 
when these are removed from the analysis. However, Knight et al. showed that the gene 292 
expression of FAS and SCD1 was increased in mice liver injected with a synthetic activator of 293 
β-oxidation (a peroxisome-proliferator activated receptor alpha (PPARα) agonist) [52]. Thus, 294 
discrepancy exists regarding the effect of PUFA in the hepatic regulation of lipogenesis.  295 
Even though fish intake did not influence mRNA levels involved in synthesis of SCD1, the 296 
data seem to fit the hypothesis that n-3 fatty acids can reduce the activity of SCD1, indirectly 297 
estimated in the present study by 18:1n-9/18:0 ratio, as has been previously reported by others 298 
[27]. However, this “desaturase index” approach is an indirect method to assess whether 299 
desaturases are inhibited, in lack of a more direct biochemical measure which is required to 300 
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demonstrate an inhibiting effect. Nevertheless, we suggest that fatty acids like EPA and DHA 301 
might serve as allosteric inhibitors. In support of this suggestion are the lowered 18:1n-9/18:0 302 
ratio after intake of fatty fish (Figure 1), the positive correlation between the 18:1n-9/18:0 303 
ratio and serum TAG (Figure 2), as well as the inverse relationship between the 18:1n-9/18:0 304 
ratio and EPA and DHA (Figure 3). It would appear that various fatty acids compete for being 305 
incorporated into PL. Although, monounsaturated fatty acids seem to be the preferred ones for 306 
PL formation [53], both EPA and DHA can be incorporated into the same position in plasma 307 
PL. By mass action it is assumed that the level of plasma PL 18:1n-9 should decrease as the 308 
levels of EPA and DHA increase. Hence, other unsaturated fatty acids in plasma PL, in 309 
addition to EPA and DHA, should be inversely associated with the 18:1n-9/18:0 ratio. This is 310 
not the case in the present study. The change in linoleic acid (18:2n-6) is in fact positively 311 
associated with the change in 18:1n-9/18:0 ratio (r = 0.5, P = 0.003), while the change in 312 
arachidonic acid (20:4n-6) shows no association at all. It is however hard to appreciate the 313 
magnitude of this possible mass effect, as compared with the other suggested explanations for 314 
obtaining reduced desaturase indexes after fish intake. Even though the intake of cod 315 
contributed to only 0.13 g of marine n-3 fatty acids per day, the level of DHA (but not EPA) 316 
in plasma PL in this group increased significantly compared to the control group (Table 3), 317 
and both the level of DHA and EPA in plasma PL correlated positively with the treatment 318 
effect on TAG (n = 30) (data not shown). The n-3 fatty acids in cod are largely incorporated 319 
into PL, in contrast to fatty fish which mainly have the fatty acids incorporated in TAG in 320 
adipose tissue. We  recently demonstrated that the bioavailability of n-3 fatty acids from krill 321 
oil (also mainly incorporated into PL [54]) is more efficient than n-3 fatty acids from fish oil 322 
(TAG) [55]. This may partly be the reason why we find positive health effects (reduced TAG 323 
concentration) also after cod intake, despite low levels of n-3 in cod. Previously, DHA has 324 
been demonstrated to have similar TAG-lowering effects as EPA [56-58] and the increase in 325 
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DHA observed in the cod group in the present study may at least partly explain the reduction 326 
in serum TAG.  327 
Also other bioactive molecules in fish, like taurine, have been suggested to have TAG 328 
reducing effects [59]. Yanagita et al. found that when HepG2 cells were stimulated with 329 
taurine, there was a reduction in TAG in both cells and medium. They also found that taurine 330 
reduced the incorporation of [
14
C]-labelled oleic acid into cellular TAG, suggesting the 331 
inhibition of TAG synthesis [59]. Or there may be a synergistic effect of taurine and marine n-332 
3 fatty acids which have the reducing effect on TAG [18]. Since our data suggest that also 333 
lean fish may reduce serum TAG, it would appear that the TAG lowering effect of lean fish is 334 
relevant to reduce CVD risk, thus supporting a previous study by Leaf and Hatcher [20]. In 335 
addition to increased TAG levels being a risk factor of CVD, HDL-C levels correlate 336 
inversely with cardiovascular risk [60]. In the present study HDL-C levels are increased after 337 
intervention with fatty fish (Table 4), which is in line with a previous report [61]. There is a 338 
well-known inverse relationship between plasma TAG levels and HDL-C [62], and this may 339 
be the reason why salmon intake might increase HDL-C.  However, there is a discrepancy in 340 
the n-3 fatty acids effect on HDL-C as reviewed by Harris [13]. 341 
In conclusion, both lean and fatty fish can increase the level of marine n-3 fatty acids in 342 
plasma PL, and reduce the serum TAG levels in healthy subjects after short term intervention. 343 
The hypotriglyceridemic action of dietary marine n-3 fatty acids can be related to a reduced 344 
18:1n-9/18:0 ratio in plasma PL, but whether gene expression in PBMC is influenced is not 345 
clarified. Our results would seem to fit the hypothesis that components in both lean and fatty 346 
fish may lower serum TAG possibly by reducing the 18:1n-9/18:0 ratio related to allosteric 347 
inhibition of SCD1 activity, rather than by influencing the synthesis of enzyme protein. 348 
349 
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FIGURE LEGENDS 563 
Figure 1: 18:1n-9/18:0 ratio in plasma phospholipids in the three intervention groups. Values 564 
are given as median with 25—75 percentiles. * P < 0.05 within-groups. 565 
 566 
Figure 2: Relationship between the change in serum triacylglycerols concentration and 567 
corresponding change in the 18:1n9/18:0 ratio in plasma phospholipids in response to the 568 
intervention (n = 30). r = 0.453, P = 0.001. 569 
 570 
Figure 3: Relationship between the increase in omega-3 fatty acids in plasma phospholipids 571 
and reduction in 18:1n-9/18:0 ratio (n = 30). r = -0.7, P < 0.001.  572 
 573 
Figure 4: The fold change PBMC mRNA levels of lipogenetic enzymes in the three 574 
intervention groups (control (n = 10), cod (n = 9), or salmon (n = 11)). Target genes are 575 
related to the mean value of the endogenous controls TBP and GUSβ. Values are given as 576 
median with 25—75 percentiles. * P < 0.05 within-groups. FAS, Fatty acid synthase; GUSβ, 577 
Glucuronidase β; PBMC, peripheral blood mononuclear cells; SCD1, Stearoyl-CoA 578 
desaturase-1; TBP, TATA binding protein. 579 
